FilingsTodayELI Lilly &
At a glance
ELI Lilly & reported 2025 revenue of $65.18B, up 44.7% from $45.04B in 2024. Over 4 years since 2021 ($28.32B), that is growth of about 23.2% a year. 2025 was the highest revenue year in this period.
In the last 12 months 5 insiders reported 0 open-market purchases and 29 sales ($78.39B). 5 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $75.91B by 10% owner Lilly Endowment Inc on Nov 17, 2025.
ELI Lilly & filed 7 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), other events (1), shareholder vote results (1) and officer or director change (1). The latest officer or director change was reported on Nov 21, 2025.
6 of the 20 investors tracked here held ELI Lilly & at the last quarter end, worth $2.27B combined. It is the largest weight for National Pension Service (Korea) (1.3% of its portfolio), followed by ARK Investment Management (0.6%). New this quarter: Duquesne Family Office. Added: National Pension Service (Korea), ARK Investment Management and Bridgewater Associates. Reduced: Renaissance Technologies.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $5.58B | $6.24B | $5.24B | $10.59B | $20.64B |
| Diluted EPS | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Dividend per share | $3.53 | $4.07 | $4.69 | $5.40 | $6.23 |
Fiscal year ends Dec 31 · incorporated in IN
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined